



T. Rogosch ^{a*}, P. Imming ^a, M. Kathmann ^b


^a Institut für Pharmazeutische Chemie, Universität Marburg, Germany

^b Institut für Pharmakologie u. Toxikologie, Universität Bonn, Germany

**Arylpropionic and arylacetic
acid derivatives as analogs of
endogenous cannabinoids**

Cannabinoids

- structure elucidation of Δ^9 -THC in 1964



- first evidence for the existence of specific binding sites for cannabinoids in 1988

Endogenous cannabinoid system

- two subtypes, CB₁ and CB₂
- CB₁ receptors are located in the CNS, predominantly on interneurons in regions for motor function, pain and learning
- CB₂ receptors are located in the peripheral nervous and immune system, e.g. on mast cells, B- and T-lymphocytes
- endogenous ligands are anandamide, 2- arachidonylglycerol and noladinether

Cannabinoid receptors

- CB₁ receptors:

Central nervous system, areas responsible for cognition, short-term memory, motor function, pain


- CB₂ receptors:

immune system, mast cells and B- and T-lymphocytes

Both receptors are coupled through G_{i/o} proteins

Inactivation system

- uptake of anandamide
- intracellular degradation, catalysed by FAAH



Endogenous cannabinoid system


takes part in:

antinociception, brain development, control of motor function, immune regulation, cell proliferation


compounds influencing the ECS are potential therapeutics for treatment of pain or neurodegenerative diseases like multiple sclerosis

K_i [nM] of endogenous ligands


	Anandamide	Noladinether	2-Arachidonylglycerol
CB ₁	89	21.2	58.3
CB ₂	371	>3000	145



Anandamide




2-Arachidonylglycerol




Noladinether


COX inhibitors




Ibuprofen



Naproxen



Flurbiprofen




Indometacin

- only *S*-enantiomers inhibit COX
- *R*-enantiomers also have analgetic potency
- mimic arachidonic acid

Arylpropionic acids interact with the endogenous cannabinoid system





- Ibuprofen and flurbiprofen inhibit the hydrolysis of anandamide at pharmacologically relevant concentrations
- R-(-)-Ibuprofen is about 2-3 times more potent than the S-(+)-enantiomer
- co-injection of PGE₂ hardly affects analgesia, but AM-251 (selective CB₁ inhibitor) suppresses it

Synthesis of ethanolamides




- reactivity of pentafluorophenyl esters towards N- nucleophiles comparable to acid chlorides, but much more stable towards O-nucleophiles
- purification via flash chromatography

Synthesised arylacetic and arylpropionic acid derivatives




Affinity of ethanolamides towards CB₁ receptors

- CB₁ receptors were extracted from the cerebral cortex of male rats
- incubation with [³H]-SR 141716
- determination of residual radioactivity




Affinity of ethanolamides towards CB₁ receptors



Affinity of ethanolamides towards CB₁ receptors

- recent studies suggest that there are two binding regions for cannabinoids at CB₁
(McAllister et al. *J.Med.Chem* **2003**, 46, 5139)
- one for aminoalkylindols and diaryl pyrazoles like SR 141716
- one for endogenous ligands like anandamide and nonclassical agonists

Affinity of ethanolamides towards CB₁ receptors



Summary

- mechanism of analgetic potency of R-enantiomers unknown yet
- possible interaction with cannabinoid system
- no affinity towards CB₁ receptors of synthesised ethanolamides

Outlook

possible affinity towards following targets - to be tested:

- CB₂ receptors (less demanding concerning substrate geometry)
- FAAH (fatty acid amidohydrolase)
- VR₁ receptors (vanilloid receptors)

synthesis of other metabolites e.g. symmetric glycerol esters